Spint3 Inhibitors
The inhibition of the protein SPINT3 involves a complex interplay of various biochemical and cellular pathways, influenced by the inhibition of specific enzymes and signaling processes. Acarbose, for instance, reduces the glycosylation of proteins, including SPINT3, leading to its functional inhibition as glycosylation is essential for SPINT3's proper folding and function. Manumycin A and LY294002 target post-translational modification and the PI3K/AKT signaling pathway, respectively. Manumycin A's inhibition of farnesyltransferase and LY294002's targeting of PI3K disrupt cellular signaling, thereby indirectly leading to SPINT3 inhibition by affecting its activity within these altered signaling cascades. U0126 and SB203580, targeting the MAPK/ERK and p38 MAP kinase pathways, respectively, alter cell growth, differentiation, and inflammatory responses, indirectly impacting SPINT3's activity by modifying the pathways and cellular states it operates in.
Furthermore, rapamycin's inhibition of mTOR and Wortmannin's targeting of PI3K lead to changes in cellular processes like protein synthesis and autophagy, indirectly inhibiting SPINT3 by influencing its operational pathways and cellular environments. PD98059, by inhibiting MEK in the MAPK/ERK pathway, and SP600125, through its inhibition of JNK, impact cellular responses to stress and cytokines, thereby altering SPINT3's activity. Y-27632, a ROCK inhibitor, affects cytoskeletal organization, indirectly leading to SPINT3 inhibition by altering cellular conditions crucial for its activity. Gefitinib and Imatinib, inhibitors of EGFR tyrosine kinase and various other tyrosine kinases respectively, modify cell growth and survival pathways. These alterations indirectly inhibit SPINT3 by changing the cellular environment and signaling pathways crucial for its functional activity. Thus, the inhibition of SPINT3 involves a multi-faceted approach, targeting various pathways and processes that indirectly influence its functional activity in the cellular context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Acarbose inhibits alpha-glucosidases, enzymes involved in the breakdown of carbohydrates. By inhibiting these enzymes, acarbose causes a reduction in glucose absorption in the intestine. This reduction in glucose can decrease the glycosylation of proteins, including SPINT3. Reduced glycosylation of SPINT3 leads to its functional inhibition as glycosylation is critical for its proper folding and function. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a farnesyltransferase inhibitor. It inhibits the post-translational modification of proteins through farnesylation. This inhibition can affect the proper localization and function of various signaling proteins, indirectly leading to the inhibition of SPINT3 activity. The disruption of signaling pathways that SPINT3 is part of results in its decreased functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 disrupts the PI3K/AKT signaling pathway, which is crucial for many cellular processes including cell survival and proliferation. This disruption indirectly inhibits SPINT3 function by altering cellular environments and signaling cascades that SPINT3 is involved in, thereby reducing its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1/2, key enzymes in the MAPK/ERK pathway. This inhibition disrupts the MAPK/ERK signaling, a pathway that plays a crucial role in cell growth and differentiation. The inhibition of this pathway can lead to altered cellular conditions that indirectly result in the inhibition of SPINT3 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, it disrupts the p38 MAPK signaling pathway, which is involved in inflammatory responses and stress-induced cellular processes. This inhibition can indirectly lead to the functional inhibition of SPINT3 by altering the cellular environment and signaling pathways that SPINT3 is part of. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR (mammalian target of rapamycin). Inhibition of mTOR signaling affects several cellular processes including protein synthesis and autophagy. This can lead to an altered cellular state that indirectly inhibits SPINT3 activity by influencing the pathways and cellular processes SPINT3 is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Similar to LY294002, it disrupts the PI3K/AKT signaling pathway. The disruption of this pathway leads to changes in cellular processes and environments, indirectly inhibiting SPINT3 by affecting the pathways and processes it participates in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway. By inhibiting this pathway, PD98059 alters cellular signaling and processes, leading to an indirect inhibition of SPINT3 activity through the disruption of pathways and cellular states SPINT3 is involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase). Inhibition of JNK signaling affects cellular responses to stress and cytokines. This alteration in signaling pathways indirectly leads to the inhibition of SPINT3 by changing the cellular environment and processes that SPINT3 functions within. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase). By inhibiting ROCK, Y-27632 affects cytoskeletal organization and cell motility. This inhibition can indirectly lead to the functional inhibition of SPINT3 by altering cellular conditions and signaling pathways that are crucial for SPINT3's activity. | ||||||